Aehr Test Systems develops, manufactures and sells systems which are designed to reduce the cost of testing and to perform reliability screening, and stress testing, burn-in or cycling, of homogeneous and heterogenous logic and memory integrated circuits (ICs), sensors and optical devices. These systems can be used to simultaneously perform parallel testing and burn-in of packaged ICs, singulated bare die or ICs still in wafer form. The company's products families include the ABTS? and FOX? systems, the WaferPak? cartridge and the DiePak? carrier. The company manufactures and markets full wafer contact test systems, test during burn-in systems, test fixtures and related accessories.

Altimmune is a clinical stage immunotherapeutics company focused on the discovery and development of products to stimulate immune responses for the prevention and treatment of diseases. The company's product candidates include: HepTcell, an immunotherapeutic for patients infected with the hepatitis B virus; ALT-702, a tumor immunostimulant designed to elicit or improve immune responses to cancers; NasoVAX, an intranasally administered recombinant influenza vaccine which stimulates an immune response; NasoShield, an anthrax vaccine designed to provide protection after a single intranasal administration; and SparVax-L, a recombinant protein-based anthrax vaccine designed to require fewer doses.

CECO Environmental is a provider of industrial air quality and fluid handling serving the energy, industrial and other markets through an asset-light business model. The company has three reportable segments: Energy Solutions, which provides offerings that improve air quality with engineered, and customized solutions for the power generation, oil and gas, and petrochemical industries; Industrial Solutions, which provides a set of air pollution control technologies to reduce carbon footprint, and lower energy consumption, among others; and Fluid Handling Solutions, which provides pump and filtration solutions that maintain safe and clean operations in harsh and toxic environments.

CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company's primary focus is on the development of its primary product candidate, Neutrolin?, for potential commercialization in the United States and other main markets. The company has in-licensed the worldwide rights to develop and commercialize Neutrolin. Neutrolin is an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as dialysis, critical/intensive care, and oncology.

Crocs is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear and accessories for men, women, and children. The company provides a variety of footwear products including sandals, flips and slides, which the company collectively refer to as sandals, shoes, and boots. The majority of shoes within the company's collection contains Croslite? material. The company's wholesale channel includes domestic and international multi-brand retailers, e-tailers, and distributors; the company's retail channel consists of company-operated stores; and the company's e-commerce channel includes company-operated e-commerce sites and third-party marketplaces.

Itron is engaged in the Industrial Internet of Things, providing solutions that enable utilities and municipalities to operate their infrastructure. The company's solutions include the deployment of smart networks, software, services, devices, sensors, and data analytics. The company's solutions and data analytics address the challenges facing the energy, water, and municipality sectors, including non-technical loss, leak detection, and environmental and regulatory compliance. The company also provides managed services, software-as-a-service, technical support services, licensing hardware technology, and consulting services. The company operates under three segments: Device Solutions, Networked Solutions, and Outcomes.

KalVista Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The company's product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company has a portfolio of oral plasma kallikrein inhibitors and developed various drug candidates into clinical trials in order to create oral therapies for both HAE and DME. The company has initiated a clinical study of KVD900 as a therapy for acute HAE attacks. The company has also commenced a clinical trial of KVD001, its DME drug candidate.

Matson is a holding company engaged in the provision of ocean transportation and logistics services. The company's Ocean transportation segment business is conducted through Matson Navigation Company, Inc., which provides a lifeline of ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska and Guam, and to other island economies in Micronesia and operates an expedited service from China to Long Beach, CA, and provides services to Okinawa, Japan and various islands in the South Pacific. The company's Logistics business is conducted through Matson Logistics, Inc., an asset-light business that provides a variety of logistics services to its customers.

MercadoLibre is engages in an online commerce ecosystem. Co.'s platform is designed to provide users with a portfolio of services to facilitate commercial transactions. Co. integrated e-commerce services includes: the MercadoLibre Marketplace, which is an automated, topically-arranged and user-friendly online commerce service; MercadoLibre Classifieds Service, which users can also list and purchase motor vehicles, vessels, aircraft, real estate and services; MercadoPago payments solution, providing a mechanism that allows its users to send and receive payments online; and MercadoLibre advertising program, which enable businesses to promote their products and services on the Internet.

Myriad Genetics is a precision medicine company acting as a trusted advisor to transform patient lives through molecular diagnostics. The company's molecular diagnostic tests include: myRisk? Hereditary Cancer for assessing the risks for hereditary cancers; BRACAnalysis? for assessing the risk of developing breast and ovarian cancer; riskScore? that improves the company's myRisk Hereditary Cancer test; GeneSight? to support psychotropic drug selection for depressed patients; Vectra?DA for assessing the disease activity of rheumatoid arthritis; and Prolaris? for assessing the aggressiveness of prostate cancer. The company also provides pharmaceutical and clinical services.

QuickLogic is a fabless semiconductor company that develops low power multi-core semiconductor platforms and intellectual property for artificial intelligence, voice and sensor processing. The company's solutions are created from its silicon platforms including its EOS?, QuickAI?, SensiML Analytics Studio, ArcticLink? III, PolarPro?3, PolarPro II, PolarPro, and Eclipse II products. The company's mature products include primarily FPGA families named pASIC?3 and QuickRAM? as well as programming hardware and design software. The company's solutions typically fall into one of three categories: Sensor Processing, Display and Visual Enhancement, and Smart connectivity.

Range Resources is a holding company. Through its subsidiaries, the company is an independent natural gas, natural gas liquids and oil company, engaged in the exploration, development and acquisition of natural gas and oil properties, located in the Appalachian and North Louisiana regions of the United States, primarily in the Marcellus Shale in Pennsylvania and the Lower Cotton Valley formation in Louisiana.

Rhythm Pharmaceuticals is a biopharmaceutical company. The company's primary product candidate is setmelanotide, which is a melanocortin-4 (MC4) receptor agonist peptide for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The company is evaluating setmelanotide for the treatment of six single gene related MC4 pathway deficiencies: pro-opiomelanocortin (POMC), leptin receptor, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.

Twist Bioscience is a synthetic biology company. The company is developing a disruptive DNA synthesis platform to industrialize the engineering of biology. The main of its platform is a proprietary technology that manufactures synthetic DNA by writing DNA on a silicon chip. The company has combined this technology with proprietary software, scalable commercial infrastructure and an e-commerce platform to create a technology platform. The company's offerings consists of two primary products that address different needs of its customers across a variety of applications: synthetic genes, oligonucleotide (oligo) pools, next generation sequencing tools and DNA libraries.